Giovanni Selvaggi

4.9k total citations · 1 hit paper
76 papers, 3.3k citations indexed

About

Giovanni Selvaggi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Giovanni Selvaggi has authored 76 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Pulmonary and Respiratory Medicine, 53 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in Giovanni Selvaggi's work include Lung Cancer Treatments and Mutations (50 papers), Lung Cancer Research Studies (27 papers) and Colorectal Cancer Treatments and Studies (16 papers). Giovanni Selvaggi is often cited by papers focused on Lung Cancer Treatments and Mutations (50 papers), Lung Cancer Research Studies (27 papers) and Colorectal Cancer Treatments and Studies (16 papers). Giovanni Selvaggi collaborates with scholars based in Italy, United States and United Kingdom. Giovanni Selvaggi's co-authors include Giorgio V. Scagliotti, Silvia Novello, Fred R. Hirsch, Scott Antonia, Matthew D. Hellmann, Fred R. Hirsch, Paolo A. Ascierto, Ariella Sasson, Chang Han and Margaret K. Callahan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Cell and Cancer.

In The Last Decade

Giovanni Selvaggi

71 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

2018 670 citations Matthew D. Hellmann, Margaret K. Callahan et al. Cancer Cell profile →

Peers

Countries citing papers authored by Giovanni Selvaggi

Since Specialization

Citations

This map shows the geographic impact of Giovanni Selvaggi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giovanni Selvaggi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giovanni Selvaggi more than expected).

Fields of papers citing papers by Giovanni Selvaggi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giovanni Selvaggi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giovanni Selvaggi. The network helps show where Giovanni Selvaggi may publish in the future.

Co-authorship network of co-authors of Giovanni Selvaggi

This figure shows the co-authorship network connecting the top 25 collaborators of Giovanni Selvaggi. A scholar is included among the top collaborators of Giovanni Selvaggi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giovanni Selvaggi. Giovanni Selvaggi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer 2023 ·Cancer Letters ·Yang Xia, (unknown), Miao Li, (unknown), Hao Zhu, (unknown), Da Miao, Qiyuan Wang, Yi Zhou, Giovanni Selvaggi, Songmin Ying, Jianjun Zhang, Huahao Shen, Xiuning Le, Wen Li	10
2	ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3 2020 ·Journal of Thoracic Oncology ·Giovanni Selvaggi, Heather A. Wakelee, Tony Mok, Yi‐Long Wu, Martin Reck, Alberto Chiappori, (unknown), Daniel Lee, В. В. Бредер, Yun Fan, С. В. Орлов, Elena Poddubskaya, (unknown), Ying Cheng, Y. Liu, Gang Wu, Li Mao, (unknown), (unknown), Leora Horn, (unknown)	32
3	P1.14-32 Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer Patients Treated with Ensartinib 2019 ·Journal of Thoracic Oncology ·Heather A. Wakelee, Karen L. Reckamp, Ticiana Leal, Alberto Chiappori, Saiama N. Waqar, (unknown), Joel W. Neal, (unknown), Kimberly Harrow, (unknown), (unknown), Giovanni Selvaggi, Leora Horn	2
4	P1.04-17 Phase I/II Study of Nivolumab and Vorolanib in Patients with Refractory Thoracic Tumors 2019 ·Journal of Thoracic Oncology ·Jonathan Whisenant, Kathryn E. Beckermann, Hossein Borghaei, Taofeek K. Owonikoko, (unknown), Lynne D. Berry, Yu Shyr, Kimberly Harrow, Chang Yin Liang, (unknown), Giovanni Selvaggi, Heather A. Wakelee, (unknown)	1
5	Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study 2019 ·Journal of Thoracic Oncology ·Enriqueta Felip, Filippo de Braud, Michela Maur, Herbert H. Loong, Alice T. Shaw, Johan Vansteenkiste, Thomas John, Geoffrey Liu, Martijn P. Lolkema, Giovanni Selvaggi, Vanessa Giannone, Pilar Cazorla, Jason Baum, O. Alejandro Balbin, (unknown), Yvonne Lau, Jeffrey W. Scott, Daniel Shao-Weng Tan	60
6	P1.14-57 Post-Ensartinib Outcomes in Refractory Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) 2019 ·Journal of Thoracic Oncology ·Hyeon Woo Kim, (unknown), Kimberly Harrow, (unknown), Giovanni Selvaggi, Eberhard Weihe, Wendy G. Mitchell, Lyudmila Bazhenova, Shiven B. Patel	0
7	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer breakdown → 2018 ·Cancer Cell ·Matthew D. Hellmann, Margaret K. Callahan, Mark M. Awad, Emiliano Calvo, Paolo A. Ascierto, Akin Atmaca, Naiyer A. Rizvi, Fred R. Hirsch, Giovanni Selvaggi, Joseph D. Szustakowski, Ariella Sasson, Ryan Golhar, Patrik Vitazka, Chang Han, William J. Geese, Scott Antonia	670
8	P1.12-21 Developing a Real-World 3L Comparator to CheckMate 032: Overall Survival (OS) in Patients with Small Cell Lung Cancer (SCLC) 2018 ·Journal of Thoracic Oncology ·Lee S. Schwartzberg, Beata Korytowsky, J.R. Penrod, Yong Yuan, Ting Gu, T. Kim Le, (unknown), Giovanni Selvaggi	4
9	A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma 2017 ·Cancer Chemotherapy and Pharmacology ·Devalingam Mahalingam, Christos Fountzilas, Jennifer L. Moseley, (unknown), Hue Tran, Romit Chakrabarty, Giovanni Selvaggi, Matthew Coffey, Brad Thompson, John Sarantopoulos	68
10	A phase 1/2 study on safety of rovalpituzumab tesirine in combination with nivolumab or nivolumab + ipilimumab in small cell lung cancer 2017 ·Annals of Oncology ·Charity D. Scripture, Giovanni Selvaggi, (unknown), Kevin A. Boynton, Satwant Lally, Tae Hyung Han, Stanford L. Peng, Scott J. Dylla	2
11	PS01.58: A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive-Stage SCLC After First-Line Chemotherapy 2016 ·Journal of Thoracic Oncology ·Taofeek K. Owonikoko, Neal Ready, Pieter E. Postmus, Martin Reck, Solange Peters, Anne Pieters, Giovanni Selvaggi, Justin Fairchild, Ramaswamy Govindan	3
12	Thymidylate Synthase But Not Excision Repair Cross-Complementation Group 1 Tumor Expression Predicts Outcome in Patients With Malignant Pleural Mesothelioma Treated With Pemetrexed-Based Chemotherapy 2010 ·Journal of Clinical Oncology ·Luisella Righi, Mauro Papotti, Paolo Ceppi, Andrea Billè, Elisa Bacillo, Luca Molinaro, Enrico Ruffini, Giorgio V. Scagliotti, Giovanni Selvaggi	126
13	Excision Repair Cross Complementing-1 and Topoisomerase IIα Gene Expression in Small-Cell Lung Cancer Patients Treated with Platinum and Etoposide: A Retrospective Study 2008 ·Journal of Thoracic Oncology ·Paolo Ceppi, Marina Longo, Marco Volante, Silvia Novello, Susanna Cappia, Elisa Bacillo, Giovanni Selvaggi, Silvia Saviozzi, Raffaele Calogero, Mauro Papotti, Giorgio V. Scagliotti	35
14	Emerging drugs for mesothelioma 2007 ·Expert Opinion on Emerging Drugs ·Giorgio V. Scagliotti, Giovanni Selvaggi	10
15	Management of bone metastases in cancer: A review 2005 ·Critical Reviews in Oncology/Hematology ·Giovanni Selvaggi, Giorgio V. Scagliotti	194
16	Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers 2005 ·Annals of Oncology ·Silvia Novello, C. Fava, P. Borasio, Luigi Dogliotti, Bernardo Cortese, (unknown), Giovanni Selvaggi, Paolo Olivo Lausi, Maria Pia Brizzi, Paola Sperone, L. Cardinale, (unknown), F. Perotto, Adriano Massimiliano Priola, Giorgio V. Scagliotti	39
17	Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy 2005 ·Lung Cancer ·Silvia Novello, Adrian Kielhorn, (unknown), Giovanni Selvaggi, Filippo de Marinis, A Maestri, Paolo Foggi, (unknown), Maurizio Tonato, Lucio Crinò, Monica Rinaldi, (unknown), Giorgio V. Scagliotti	18
18	Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA‐bulky N2 and Stage IIIB nonsmall cell lung carcinoma 2003 ·Cancer ·Federico Cappuzzo, Giovanni Selvaggi, Vanesa Gregorc, Francesca Mazzoni, (unknown), Maria Rita Migliorino, Silvia Novello, A Maestri, Filippo de Marinis, Samir Darwish, Verena De Angelis, Fabrizio Nelli, Stefania Bartolini, Giorgio V. Scagliotti, Maurizio Tonato, Lucio Crinò	34
19	Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer 2003 ·Annals of Oncology ·Giovanni Selvaggi, Silvia Novello, Valter Torri, E Leonardo, Paolo De Giuli, P. Borasio, C Mossetti, Francesco Ardissone, Paolo Olivo Lausi, Giorgio V. Scagliotti	237
20	Multidrug resistance in non-small-cell lung cancer 1999 ·Annals of Oncology ·Giorgio V. Scagliotti, Silvia Novello, Giovanni Selvaggi	70

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact